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Background: Randomised controlled trials are widely accepted as the gold standard method to evaluate medical
interventions, but they are still open to bias. One such bias is the effect of patient’s preference on outcome
measures. The aims of this study were to examine whether patients’ treatment preference affected clearance of
plantar warts and explore whether there were any associations between patients’ treatment preference and
baseline variables in the EverT trial.
Methods: Two hundred and forty patients were recruited from University podiatry schools, NHS podiatry clinics
and primary care. Patients were aged 12 years and over and had at least one plantar wart which was suitable for
treatment with salicylic acid and cryotherapy. Patients were asked their treatment preference prior to
randomisation. The Kruskal-Wallis test was performed to test the association between preference group and
continuous baseline variables. The Fisher’s exact test was performed to test the association between preference
group and categorical baseline variables. A logistic regression analysis was undertaken with verruca clearance
(yes or no) as the dependent variable and treatment, age, type of verruca, previous treatment, treatment preference
as independent variables. Two analyses were undertaken, one using the health professional reported outcome
and one using the patient’s self reported outcomes. Data on whether the patient found it necessary to stop the
treatment to which they had been allocated and whether they started another treatment were summarised by
treatment group.
Results: Pre-randomisation preferences were: 10% for salicylic acid; 42% for cryotherapy and 48% no treatment
preference. There was no evidence of an association between treatment preference group and either patient
(p=0.95) or healthcare professional (p=0.46) reported verruca clearance rates. There was no evidence of an
association between preference group and any of the baseline variables except gender, with more females
expressing a preference for salicylic acid (p=0.004). There was no evidence that the number of times salicylic
acid was applied was different between the preference groups at one week (p=0.89) or at three weeks (p=0.24).
Similarly, for the number of clinic visits for cryotherapy (p=0.71)
Conclusions: This secondary analysis showed no evidence to suggest that patients’ baseline preferences affected
verruca clearance rates or adherence with the treatment.
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The Randomised Controlled Trial (RCT) is widely
accepted as being the ‘gold standard’ design for evaluat-
ing the effectiveness of a medical intervention [1]. In an
RCT patients are randomly allocated to a study group so
that, on average, the groups formed are equivalent in
all known and unknown characteristics that may affect
outcome. This process should eliminate selection bias,
however, it is possible for other types of bias to be intro-
duced after the randomisation process [2-4].
One potential form of bias is that of patients’ prefer-
ence, which may adversely affect both the external and
internal validity of the trial. The external validity of a
trial may be affected if large numbers of patients, who
have a strong preference for a particular treatment,
refuse to take part in the study as they are not guaran-
teed to receive their treatment of choice [5]. In this case,
the generalisabilty of the study’s findings may be limited.
The internal validity of a study can also be affected de-
pending on whether or not patients who agree to be ran-
domised receive their preferred treatment. Patients who
receive their preferred treatment may be more motivated
and comply better with the treatment and report better
outcomes compared to those who do not receive their
preferred treatment. Furthermore, those patients who
do not receive their preferred treatment may experience
resentful demoralisation and may be more likely to
drop out of the study, resulting in differential loss to
follow-up [6].
Whilst the randomisation process will ensure that
patients with different treatment preferences are allo-
cated equally between the groups, it is unable to deal
with the effect the patients’ treatment preference may
have on the outcome measures after randomisation. In
order to make comparisons between patients with and
without a treatment preference, some trialists have used
the patient preference design [7,8]. In this design
patients who have a strong preference for one treatment
are allocated to their preferred treatment and only
patients who are indifferent to which treatment they re-
ceive are randomised conventionally. Such a design
allows for the examination of patient characteristics
associated with preference to be explored. There are
however, several limitations to this design. First, it is
likely that selection bias will be introduced into the pre-
ference arms of the study as they have not been formed
by randomisation. Second, it is not known for certain
that patients’ preference will affect outcomes, so using
this design might mean patients are lost from random-
isation needlessly. Finally the design may increase the
size and cost of the trial.
An alternative trial design is that of a fully randomised
preference trial [6]. In this design all patients who give
their consent to participate in the trial are randomised,but their treatment preference is recorded prior to ran-
domisation. This then makes it possible to take treat-
ment preference into account during the analysis of
the trial.
Several trials have been undertaken using this approach
to assess the effect of patients’ preference on out-
come [9,10].
A systematic review and individual patient data meta-
analysis in musculoskeletal trials demonstrated that
treatment preferences among patients can modify treat-
ment outcomes [11]. To date, the effect of patients’ pre-
ference for type of plantar wart treatment on the
outcome of the intervention has not been explored. We
undertook a randomised controlled trial to assess the
clinical and cost effectiveness of cryotherapy using liquid
nitrogen and salicylic acid to treat plantar warts in which
the patients’ treatment preference was recorded prior to
randomisation [12]. The results of the effect of patients’
treatment preference on the outcome of the intervention
are reported here.
Methods
This was a multicentre, two arm randomised controlled
open trial. The study was approved by Trent Multicentre
Research Ethics Committee (MREC reference 04/mre04/
59), Galway Research Ethics Committee and local
research ethics committees, Medicines and Healthcare
products Regulatory Agency, Irish Medicines Board and
local Research and Development Trusts. All patients
provided written informed consent prior to being
enrolled in the study.
Detailed methods [13] and the main trial results have
been published elsewhere [12,14]. In brief, 13 sites
within the UK and one in the Republic of Ireland
recruited 240 patients from University podiatry schools,
NHS podiatry clinics and primary care. Patients were eli-
gible for the study if they were aged 12 years and over
and had at least one plantar wart, which in the opinion
of the healthcare professional was suitable for treatment
with both salicylic acid and cryotherapy. Once written
informed consent had been obtained from the patient,
baseline data were collected prior to the patient being
randomised. This included the treating healthcare pro-
fessional asking patients whether they had a treatment
preference and if so, which treatment did they prefer;
salicylic acid, cryotherapy or no treatment preference.
Patients were then randomly allocated equally to receive
either cryotherapy using liquid nitrogen, for a maximum
of four sessions, two to three weeks apart, or daily self-
treatment with an over the counter 50% salicylic acid
treatment for up to eight weeks. Simple randomisa-
tion was used with the allocation sequence generated
by a computer which was provided by the York Trials
Unit using a remote, secure telephone or on-line
Table 1 Number (percent) of patients in each treatment
group with their treatment preference
Treatment
preference
Treatment randomised
Cryotherapy Salicylic acid Overall
Salicylic acid 10 (9.7) 18 (15.7) 28 (12.8)
Cryotherapy 43 (41.8) 43 (37.4) 86 (39.5)
No preference 50 (48.5) 54 (47.0) 104 (47.7)
Total 103 115 218*
*22 randomised participants had missing preference data.
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up at one, three, twelve and twenty-four weeks after
entering into the study. The primary outcome was
complete clearance of all plantar warts at 12 weeks after
randomisation as observed on digital photos by blinded
healthcare professionals and by a healthcare professional
assessment performed at the recruiting centres. Second-
ary outcomes for the study included patient self-
reported clearance of verruca(e) at 12 and 24 weeks and
patient self-reported time to clearance of verruca(e).
All analyses were conducted on an intention to treat
basis, including all patients in the groups to which they
were randomised. All analyses were conducted in SAS
version 9.2 (SAS Institute, NC, USA) and SPSS version
17.0.2 (SPSS) using two-tailed significance tests at the
5% significance level.
The baseline data were summarised descriptively by
treatment preference group. The Kruskal-Wallis test was
performed to test the association between continuous
baseline variables and treatment preference group and
to test the association between measures of compliance
(number of times salicylic acid applied and attendance at
clinic visits for cryotherapy) and preference group. The
Kruskal-Wallis test was used as the data did not meet
the assumptions for parametric tests. The Fisher’s exact
test was performed to test the association between
categorical baseline variables and treatment preference
group and to test the association between drop out and
treatment preference group. The Fisher’s exact test was
used as some of the comparisons had less than 80% of
expected frequencies greater than 5 and/or at least one
expected frequency less than 1. We fitted a logistic
regression model with verruca clearance (yes/no) as the
primary outcome and treatment, age, type of verruca,
previous treatment, treatment preference and the inter-
action term between randomised treatment and treat-
ment preference as covariates. Two analyses were
undertaken, one using the health professional reported
outcome at 12 weeks and one using patient’s self
reported outcomes at 12 weeks.
Data on whether the patient found it necessary to
stop the treatment to which they had been allocated
and whether they started another treatment were sum-
marised by treatment group.
Results
In total 240 eligible patients were recruited to the study
between November 2006 and January 2010. One hun-
dred and seventeen patients were allocated to the cryo-
therapy group and 123 to the salicylic acid group. Two
hundred and eighteen patients responded to the ques-
tion about pre-randomisation treatment preference. One
hundred and fourteen (47.5%) patients expressed a treat-
ment preference at baseline; of those 114 patients,twenty-eight (12.8%) expressed a preference for salicylic
acid and 86 (39.5%) patients expressed a preference
for cryotherapy. One hundred and four (47.7%) patients
did not have a treatment preference at baseline. Twenty
two (9.2%) patients did not respond to this ques-
tion. The number of patients allocated to each group
along with their treatment preference is summarised in
Table 1. The groups were balanced at baseline for treat-
ment preference.
Tables 2 and 3 present the descriptive statistics for the
baseline characteristics of patients and their presenting
plantar warts between the three treatment preference
groups along with the tests of association. The results
from the Kruskal-Wallis test demonstrate that there was
no evidence of an association between treatment prefer-
ence and age (p=0.76), number of verrucae at baseline
(p=0.5) and duration of the current verruca (p=0.43).
The results from the Fisher’s exact test demonstrate that
there was no evidence of an association between treat-
ment preference and type of verruca (p=0.73), previous
treatment of verruca (p=0.78), reasons for seeking treat-
ment and type of previous treatment. However, there
was evidence of an association between treatment pre-
ference and gender (p=0.004), with more females expres-
sing a preference for salicylic acid.
When we included an interaction term between ran-
domised treatment and preferred treatment we found no
evidence to suggest that patients’ preferences at baseline
influenced health professional reported primary outcome
(p=0.46) or the patient reported outcome (p=0.95).
Overall few patients reported stopping their original
treatment (n=21, 11.5%). Of those that did, 16 patients
were in the salicylic acid group and five in the cryother-
apy group. Only three of the 21 patients started a differ-
ent treatment (2 in the salicylic acid group and 1 in the
cryotherapy group).
Primary outcome data were reported for 229 (95.4%)
patients at 12 weeks with 206 (90.0%) having a blinded
outcome assessment. Primary outcome data were un-
available for the remaining 11 participants (4 in the sali-
cylic acid group and 7 in the cryotherapy group) due to
the patients dropping out of the study. Of these 11, two
had their preferred treatment, three did not have their
Table 2 Baseline characteristics of patients with plantar warts according to treatment preference
Characteristic Treatment preference P value
Salicylic acid (N=28) Cryotherapy (N=86)* No preference (N=104)
Age (years)
Median (interquartile range) 24.8 (16.6, 52.4) 24.2 (17.4, 41.9) 22.9 (18.6, 38.4) 0.76*
Gender
Male 3 (10.7) 37 (44.1) 33 (31.7) 0.004
Female 25 (89.3) 47 (56.0) 71 (68.3)
Reasons for seeking treatment**
Painful 11 (39.9) 46 (54.8) 67 (64.4) 0.05
Unable to go swimming 8 (28.6) 21 (25.0) 32 (30.8) 0.69
Unable to participate in other sports 7 (25.0) 17 (20.2) 20 (19.2) 0.82
Other 16 (57.1) 39 (46.4) 40 (38.5) 0.18
Values are n (%) unless otherwise stated.
*2 participants had missing characteristics data.
**Patients may have more than one reason for seeking treatment.
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five participants did not express their treatment prefer-
ences. There was no evidence of an association between
missing data for the primary outcome and whether a
participant received their preferred treatment or not
(p=0.17).Table 3 Baseline characteristics of plantar warts according to
Characteristic
Salicylic acid
Type of verruca
Mosaic 5/28 (17.9)
Non-mosaic 23/28 (82.1)
Duration of verruca (months)
N 26
Mean(sd) 30.7 (27.5)
Median (interquartile range) 24.0 (12.0, 39.0)
Number of verrucae at baseline
N 28
Mean (sd) 4.3 (4.5)
Median (interquartile range) 3.0 (1.0, 5.5)
Previous treatment for current verruca
Yes 23/28 (82.1)
No 5/28 (17.9)
Type of previous treatment*
Self-treatment 21/23 (91.3)
Podiatrist/chiropodist 5/23 (21.7)
GP 10/23 (43.5)
Trial investigating verruca treatments 0/23 (0.0)
Other 3/23 (13.0)
Values are n/N (%) unless otherwise stated.
* Patients may have more than one previous verruca treatment.Table 4 reports the treatment adherence for patients
allocated to receive salicylic acid and cryotherapy. There
was no evidence that the number of times salicylic acid
was applied was different between the preference groups
at one week (p=0.89) or at three weeks (p=0.24). There
was also no evidence that the number of clinic visits fortreatment preference
Treatment preference P value
Cryotherapy No preference
16/86 (18.6) 24/104 (23.1) 0.73
70/86 (81.4) 80/104 (76.9)
80 100
22.9 (19.6) 26.6 (27.3) 0.43
18.0 (9.5, 29.0) 16.8 (8.5, 36.0)
86 101
3.8 (6.6) 3.3 (3.3) 0.50
2.0 (1.0, 4.0) 2.0 (1.0, 4.0)
66/84 (78.6) 79/104 (76.0) 0.78
18/84 (21.4) 25/104 (24.0)
53/66 (80.3) 73/80 (91.3) 0.15
23/66 (34.9) 20/79 (25.3) 0.34
30/66 (45.5) 27/80 (33.8) 0.32
2/66 (3.0) 0/79 (0.0) 0.41
6/66 (9.1) 5/79 (6.3) 0.50
Table 4 Treatment compliance (number of times salicylic
acid applied or number of clinic visits for cryotherapy)
Mean (sd) Median
(min, max)
p-value
Randomised to cryotherapy
Preferred cryotherapy 3.58 (0.73) 4 (1, 4) 0.71
Preferred salicylic acid 3.60 (0.52) 4 (3, 4)
No preference 3.68 (0.79) 4 (1, 5)
Randomised to salicylic acid
Week 1
Preferred salicylic acid 6.44 (1.03) 7 (4, 7) 0.89
Preferred cryotherapy 6.53 (1.06) 7 (2, 7)
No preference 6.23 (1.63) 7 (0, 7)
Week 3
Preferred salicylic acid 6.27 (2.52) 7 (0, 12) 0.24
Preferred cryotherapy 5.79 (3.55) 6 (0, 22)
No preference 5.04 (2.23) 6 (0, 7)
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(p=0.71).
Discussion
The results from this secondary analysis found no evi-
dence to suggest that patients’ baseline treatment prefer-
ence affected outcome and so receiving the preferred
treatment did not confer any additional benefits in those
who expressed a preference. The findings of this analysis
are not totally unexpected since the primary outcome
measure in this study ie clearance of verruca(e) was
undertaken by independent blinded healthcare profes-
sionals. Such reported measures are unlikely to be influ-
enced by the patients’ preference compared to patient
self-reported outcomes other than indirectly through dif-
ferences in levels of adherence. In order to investigate
this further, we explored whether there was an associ-
ation between (a) healthcare professional reported out-
comes and patient treatment preference and (b) patient
reported outcomes and treatment preference. In both
cases there was no evidence of an association between
outcome and treatment preference.
In this study only 114 (52%) patients expressed a treat-
ment preference at baseline. Of these 114 patients, more
preferred cryotherapy (n=86) than salicylic acid (n=28)
with just over a half of these patients receiving their pre-
ferred treatment. Among those with no baseline prefer-
ence, similar numbers were randomised to the two
treatment groups. The difference in treatment prefer-
ence could be due to several reasons. First, many of the
patients who took part in the trial were identified from
referrals to cryotherapy clinics. These patients had
already decided that cryotherapy was a suitable form
of treatment for them and expected this treatment.Secondly whilst we did not collect data on what
informed patients’ treatment preference Thomas et al.
[15] have reported these findings from a survey of
patients within primary care. They reported the most
common reason (35%) for patients seeking treatment
was to get rid of plantar warts quickly. So patients could
have believed that cryotherapy was the more effective
form of treatment. Finally, results from the same survey
reported the second most common reason for seeking
treatment (21%) was due to patients preferring a ‘profes-
sional person’ to treat their plantar wart. The fact that
both treatments were frequently used within normal
practice and were not considered to be novel or new
treatments may have contributed towards almost half of
the patients (48%) not having a treatment preference.
We anticipated that the majority of patients in this study
would have received some form of previous treatment
prior to taking part in the study and that the efficacy
and experiences of these treatment regimens, would
inform future treatment preferences. The majority of
patients (n = 168, 78%) reported having received
some form of previous treatment. Of those 168 patients,
147 (87%) had used some form of self-treatment
(salicylic acid or a freezing agent) whilst 48 (29%) and
66 (39%) patients had received treatment from a podia-
trist or their GP respectively. There was no evidence of
an association between treatment preference and age,
duration of verruca, type of verruca and previous treat-
ment of verruca. However, there was evidence of an
association between treatment preference and gender,
with more females expressing a preference for salicylic
acid. As we did not collect data on what informed treat-
ment preference we are unable to report why patients
expressed this preference and this could be a chance
finding. However, it has been reported that male gender
is a predictor for wishing to have a passive role in clin-
ical decision making (i.e., to receive information with a
view of following the doctor's advice) [16] and this may
tentatively be extrapolated to receiving a clinician deliv-
ered treatment.
External validity
During the course of the study we attempted to collect
data on patients who were screened for the study but
not enrolled. Two hundred and eighty-four potential
patients were approached to take part in the study, 44 of
whom were excluded. Approximately half of these (23)
were excluded as they were unable to be treated with
the trial treatments and only six patients were not inter-
ested in taking part in the study. It is possible that
data from patients with a strong treatment preference
were not collected. For example patients who were
approached to take part in the trial whilst requesting
treatment at their local GP cryotherapy clinic, may not
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understandably concentrated their efforts on collecting
data from patients participating in the study. Or patients
with strong treatment preferences could have accessed
both treatments outside of the study.
The participants in this study had longstanding plantar
warts, most of which had been self treated, which is typ-
ical of patients presenting to healthcare professionals.
These patients were recruited from 14 centres across
England, Scotland and Ireland from podiatry clinics,
general practice and from the community. We can
therefore be confident that the results of this study are
broadly generalisable and that the study has external
validity across the UK and Ireland.
Internal validity
There was a low incidence of patients stopping their
original treatment and of seeking alternative treatments.
Only 21 patients reported stopping their treatment.
Since only three (15%) of these 21 patients reported
starting another treatment it is unlikely that dilution bias
has been introduced. In addition patients who did not
receive their preferred treatment did not have higher
attrition rates than those who did receive their preferred
treatment. We found no evidence to suggest that
patients who expressed a treatment and received their
preferred treatment adhered to their treatment better
than those who did not receive their preferred treatment.
Comparison with other studies
The proportion of patients who expressed a treatment
preference in this study is similar to the median prefer-
ence rate of 56% reported in a systematic review of
patients’ preferences within randomised trials [11].
Unlike our study which found no evidence to suggest
that patients’ treatment preference affected outcome,
this review concluded that patients’ preferences for
treatment may influence outcome [10,11]. However, the
review differed from our study in two ways. First the
therapeutic area of the review, which focused mainly on
musculoskeletal trials, was different to that reported
here. Secondly, the review only included trials reporting
self-reported outcomes as the primary outcome, whereas
the primary outcome for this trial was healthcare pro-
fessional reported clearance of verrucae. Trials using
self-reported outcomes may be expected to be more
influenced by patients’ preference as opposed to out-
comes reported by blinded independent clinicians, or
clearance of disease as used in the EverT trial.
Strengths and limitations
As far as we are aware, this is the first randomised con-
trolled trial assessing the effect of patients’ preference
on the clearance of verrucae. Our study does have somepotential limitations. First this study was not powered to
detect a difference in preference-treatment interaction
and so there may have been insufficient patients in the
study to detect a difference, if one existed. Nevertheless,
the results of this study could be included with other
studies in a meta-analysis to assess the effect of prefer-
ences on outcome. Second, the patient’s treatment
preference was elicited by the treating healthcare pro-
fessional, so there was the possibility that their views,
(either knowingly or unknowingly) could influence the
patients. Care had to be taken when eliciting a response
about preference that patients understood and agreed to
being randomly assigned to either group. Expressing a
particular preference for a treatment would not neces-
sarily result in them receiving the treatment. In order
to minimise the possibility of this occurring, clinicians
were made aware of this potential limitation during the
trial training.Conclusions
This trial showed no evidence that treatment preference
affected outcomes in the EverT trial. The method
employed in this study to explore the effect of patients’
treatment preference on outcome could be used in other
trials, and may be a more straightforward alternative to
the more complex ‘patient preference’ trial design.
Results of this and other trials could then be combined
in further work to assess the treatment effects of
patients’ preferences in different clinical conditions.
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